BCRX
What one share of Biocryst Pharmaceuticals holds
Biological Products, (No Diagnostic Substances)
We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions.
Biocryst Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.02 |
|---|---|
| Profit | −$1.64 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | $1.60 |
| Cash and investments | $0.61 |
| Debt | $1.56 |
| Book value | −$1.78 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.11 | −$1.09 | $0.00 | −$0.81 | — | −$0.11 |
| 2021 | $0.88 | −$1.03 | $0.01 | −$0.81 | — | −$0.58 |
| 2022 | $1.46 | −$1.33 | $0.01 | −$0.88 | — | −$1.57 |
| 2023 | $1.72 | −$1.18 | $0.01 | −$0.51 | — | −$2.21 |
| 2024 | $2.18 | −$0.43 | $0.01 | −$0.26 | — | −$2.28 |
| 2025 | $4.00 | $1.21 | $0.01 | $1.58 | — | −$0.56 |